Skip to main content

Table 2 ECMO settings and relevant coagulation factors

From: Comparison of anticoagulation strategies for veno-venous ECMO support in acute respiratory failure

 

ALL

( n = 218)

High-dose group

( n = 117)

Low-dose group

( n = 101)

P value

ECMO device

   

 < 0.001

 CardioHelp

 

31 (26.5)

99 (98)

 

 RotaFlow

 

86 (73.5)

2 (2)

 

Canula site out

    

 Jugular vein

3 (1.4)

3 (2.6)

0

 

 Femoral vein

215 (98.6)

114 (97.4)

101 (100)

 

Canula site in

    

 Jugular vein

135 (61.9)

113 (96.6)

22 (21.8)

 

 Subclavian vein

2 (0.9)

2 (1.7)

0

 

 Femoral vein

81 (37.2)

2 (1.7)

79 (78.2)

 

Canula size out

23 (23–35)

23 (23–23)

25 (25–25)

 < 0.001

Canula size in

17 (17–23)

17 (17–17)

23 (21–25)

 < 0.001

ECMO runtime, median (IQR), days

9 (5–14)

8 (5–12)

11 (7–17)

0.003

ECMO flow, median (IQR), liter per minute

3.8 (3.3–4.4)

3.5 (2.8–3.9)

4.4 (3.8–4.9)

 < 0.001

Days from mechanical ventilation to ECMO implantation, median (ICR)

1 (0–3)

1 (0–3)

1 (0–4)

0.185

Antiplatelet therapy pre-ECMO

    

Aspirin

31 (14)

13 (11)

18 (18)

0.157

P2Y12-inhibitors

6 (3)

2 (2)

4 (4)

0.311

Antiplatelet therapy during ECMO, n (%)

    

Aspirin

27 (12)

9 (8)

18 (18)

0.024

P2Y12-inhibitors

5 (2)

0

5 (5)

0.015

Baseline fibrinogen, g/L (IQR)

4.7 (3.3–6.2)

6.7 (3.3–6.4)

4.8 (3.4–6.1)

0.611

Minimal fibrinogen, g/L (IQR)

2.2 (1.4–3.4)

2.5 (1.6–3.5)

2.0 (1.2–3.4)

0.030

Baseline d-dimers, mg/L (IQR)

7.6 (3.6–15.4)

5.4 (2.6–12.7)

8.3 (4.4–16.5)

0.010

Maximum d-dimers, mg/L (IQR)

30 (19.3–35)

28.5 (13–30)

35 (33.4–35)

 < 0.001

Baseline antithrombin III, % (IQR)

67 (53–86)

79 (60–93)

60 (44–75)

 < 0.001

Minimum antithrombin III, % (IQR)

59 (45–76)

69 (56–84)

48 (37–62)

 < 0.001

Antithrombin III substitution, n (%)

29 (13.3)

8 (6.8)

21 (21)

0.002

Baseline thrombocyte count, thousand / µL (IQR)

174 (101–265)

167 (109–269)

183 (97–263)

0.878

Minimum thrombocyte count, thousand / µL (IQR)

62 (36–88)

65 (33–106)

60 (40–81)

0.868

Received PCC, n (%)

36 (16.5)

8 (6.8)

26 (25.7)

 < 0.001

Received tranexamic acid, n (%)

113 (51.8)

61 (52.1)

52 (51.5)

0.924

  1. ECMO extracorporeal membrane oxygenation, IQR interquartile range, PCC prothrombin complex centrates